Ray Therapeutics Raises $125 Million Series B to Advance Optogenetic Vision Programs

According to a recent LinkedIn post from 4BIO Capital, portfolio company Ray Therapeutics, Inc. has reportedly closed an upsized and oversubscribed $125 million Series B financing to advance its optogenetic vision restoration platform. The post links this funding to Ray’s recent RMAT Designation from the U.S. FDA for RTx‑015 in retinitis pigmentosa, which is presented as evidence of clinical and regulatory momentum.

The LinkedIn post indicates that the proceeds are expected to support two clinical‑stage programs, RTx‑015 for retinitis pigmentosa and RTx‑021 for macular diseases such as Stargardt disease and geographic atrophy age‑related macular degeneration. For investors in 4BIO Capital, this suggests an increasing exposure to late‑stage ophthalmology gene therapy assets, which may enhance the value potential of its portfolio but also concentrate risk around clinical and regulatory outcomes.

The oversubscribed nature of the round, as described in the post, implies strong venture and crossover investor interest in Ray Therapeutics’ platform and the broader optogenetics field. If the clinical programs progress successfully, this could position Ray as a differentiated player in retinal degeneration and potentially support higher valuations for both the company and early investors such as 4BIO Capital.

At the same time, the focus on severe retinal diseases underscores that future returns remain highly contingent on trial readouts, durability of response, and payer acceptance in niche indications. The RMAT designation referenced in the post may provide an expedited regulatory pathway in the U.S., potentially shortening time to market, but it does not guarantee approval and keeps regulatory risk material for investors monitoring 4BIO Capital’s exposure.